Jazz Pharmaceuticals Public Limited Company filed a Form 8-K on October 26, 2026, disclosing an estimated pre-tax acquired in-process research and development charge of approximately $755 million related to its completed acquisition of Actio Biosciences, Inc.

Key Highlights

  • Acquisition completed: Jazz Pharmaceuticals closed its acquisition of Actio Biosciences, Inc., a Delaware corporation, on September 15, 2026.
  • Estimated IPR&D charge: The company currently estimates a pre-tax acquired in-process research and development expense of approximately $755 million for the third quarter of 2026.
  • EPS impact: The charge is estimated to represent an unfavorable impact of approximately $11.00 to both GAAP EPS and non-GAAP adjusted EPS for Q3 2026.
  • Not tax deductible: According to the filing, the expected IPR&D charge is not tax deductible.
  • Results not finalized: The company disclosed that its Q3 2026 results have not been finalized and are subject to financial statement closing procedures.
  • Signed by CFO: The report was signed by Philip L. Johnson, Executive Vice President and Chief Financial Officer.

Jazz Pharmaceuticals Estimates Q3 2026 Financial Impact of Actio Biosciences Acquisition

Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ), an Irish public limited company, filed a current report on October 26, 2026, under Item 2.02 (Results of Operations and Financial Condition), disclosing estimated financial impacts connected to its acquisition of Actio Biosciences, Inc. According to the filing, that acquisition was completed on September 15, 2026. The company currently estimates that its financial results for the quarter ended September 30, 2026, will include a pre-tax acquired in-process research and development ("IPR&D") expense of approximately $755 million.

The filing stated that the expected IPR&D charge is not tax deductible and is estimated to represent an unfavorable impact of approximately $11.00 to both GAAP earnings per share and non-GAAP adjusted EPS for Q3 2026. The company cautioned that its results for the quarter have not been finalized and "are subject to the Company's financial statement closing procedures," adding that "there can be no assurance that actual results will not differ from the preliminary estimated results described herein." The filing further noted that the disclosed information "does not present all information necessary for a complete understanding of the Company's results for the quarter ended September 30, 2026."

The filing also contained disclosures about the company's non-GAAP adjusted EPS measure, describing it as non-GAAP adjusted net income divided by non-GAAP weighted-average diluted shares outstanding. The company stated this measure excludes intangible asset amortization, share-based compensation expense, and certain other specified items in certain periods, and adjusts for the income tax effect of non-GAAP adjustments. The filing included the company's own forward-looking statements regarding the estimated IPR&D charges and related EPS impacts, which, according to the filing, "involve risks and uncertainties such that actual results may differ materially from these statements."

What Was Disclosed

Jazz Pharmaceuticals disclosed an estimated pre-tax IPR&D charge of approximately $755 million for Q3 2026, tied to the September 15, 2026 closing of its Actio Biosciences acquisition, with an estimated $11.00 unfavorable impact per share on both GAAP and non-GAAP EPS. Final results remain pending.